Circassia Pharmaceuticals (NIOX) Price & Analysis

Compare

13 Followers

NIOX Stock Chart & Stats

Day’s Range― - ―

52-Week Range53.40p - 80.00p

Previous CloseN/A

Volume260.54K

Average Volume (3M)1.27M

Market Cap

£271.56M

Enterprise ValueN/A

Total Cash (Recent Filing)£21.50M

Total Debt (Recent Filing)£900.00K

Price to Earnings (P/E)77.3

Beta1.15

Next Earnings

Sep 11, 2025

EPS EstimateN/A

Last Dividend Ex-Date

May 15, 2025

Dividend Yield1.47%

Share Statistics

EPS (TTM)<0.01

Shares Outstanding399,355,960

10 Day Avg. Volume849,461

30 Day Avg. Volume1,271,495

Financial Highlights & Ratios

PEG Ratio161.62

Price to Book (P/B)338.30

Price to Sales (P/S)0.00

P/FCF Ratio1.96K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£85.67

Price Target Upside27.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

---

Circassia Pharmaceuticals News

PremiumCompany Announcements

NIOX Group Reports Strong Start to 2025 and Outlines Strategic Priorities

1d ago

PremiumCompany Announcements

NIOX Group Announces Final Dividend Timetable for 2024

21d ago

PremiumCompany Announcements

NIOX Group Announces 2025 AGM Details

1M ago

PremiumCompany Announcements

Niox Group PLC Announces Change in Voting Rights

1M ago

PremiumCompany Announcements

NIOX Group’s Director-Related Share Transaction Announced

1M ago

PremiumRatings

Circassia Pharmaceuticals: Buy Rating Reaffirmed Despite Withdrawn Offer, 9.4% Upside Potential

1M ago

PremiumCompany Announcements

NIOX Group Discontinues Private Sale Amid Economic Challenges

1M ago

PremiumCompany Announcements

NIOX Group Seeks Block Admission for Share Trading on AIM

1M ago

See All GB:NIOX News

---

Bulls Say, Bears Say

Bulls Say

EarningsNIOX's fiscal year trading update confirms another solid period of growth, with revenues increasing by 14% to £41.8 million, in line with consensus expectations.

Financial PerformanceStronger-than-expected operational leverage saw adjusted EBITDA grow by 21% to £13.8 million, exceeding consensus estimates.

ValuationNIOX trades at a significant discount to peers, with a 2025 estimated price-to-earnings ratio of approximately 13 times, considered too cheap given the company's growth and margin profile.

Bears Say

AcquisitionDiscussions are early stages with no formal offer as yet from Keensight.

Macro EnvironmentKeensight Capital has announced that it does not intend to make a firm offer for the business at this stage due to the current uncertain macroeconomic environment.

Share PriceA level of weakness in the share price is anticipated due to recent newsflow and share price action related to it.

---

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.89% Insiders

―

Mutual Funds

<0.01% Other Institutional Investors

98.92% Public Companies and

Individual Investors

Detailed Ownership Overview >

NIOX FAQ

What was Circassia Pharmaceuticals’s price range in the past 12 months?

Circassia Pharmaceuticals lowest share price was 53.40p and its highest was 80.00p in the past 12 months.

What is Circassia Pharmaceuticals’s market cap?

Circassia Pharmaceuticals’s market cap is £271.56M.

When is Circassia Pharmaceuticals’s upcoming earnings report date?

Circassia Pharmaceuticals’s upcoming earnings report date is Sep 11, 2025 which is in 119 days.

How were Circassia Pharmaceuticals’s earnings last quarter?

Circassia Pharmaceuticals released its earnings results on Apr 01, 2025. The company reported -0.002p earnings per share for the quarter, missing the consensus estimate of N/A by -0.002p.

Is Circassia Pharmaceuticals overvalued?

According to Wall Street analysts Circassia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Circassia Pharmaceuticals pay dividends?

Circassia Pharmaceuticals pays a Annually dividend of 1.25p which represents an annual dividend yield of 1.47%. See more information on Circassia Pharmaceuticals dividends here

What is Circassia Pharmaceuticals’s EPS estimate?

Circassia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Circassia Pharmaceuticals have?

Circassia Pharmaceuticals has 399,355,960 shares outstanding.

What happened to Circassia Pharmaceuticals’s price movement after its last earnings report?

Circassia Pharmaceuticals reported an EPS of -0.002p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.789%.

Which hedge fund is a major shareholder of Circassia Pharmaceuticals?

Currently, no hedge funds are holding shares in GB:NIOX

---

Circassia Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

4.55%

Trailing 12-Months

Asset Growth

-25.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Circassia Pharmaceuticals

Circassia Pharmaceuticals, operating under the brand NIOX, is a specialty biopharmaceutical company focused on the development and commercialization of products for respiratory diagnostics and management. The company primarily operates in the healthcare sector, with its core product being NIOX VERO, a leading device used by healthcare professionals for measuring fractional exhaled nitric oxide (FeNO) to assess airway inflammation in patients with conditions such as asthma.

---

NIOX Stock 12 Month Forecast

Average Price Target

85.67p

▲(27.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"26p","91":"91p","42.25":"42.3p","58.5":"58.5p","74.75":"74.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">90.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">85.67p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">77.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,42.25,58.5,74.75,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2018","6":"Sep<br/>2023","9":"Sep<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.4,76.52307692307693,77.64615384615385,78.76923076923077,79.8923076923077,81.01538461538462,82.13846153846154,83.26153846153846,84.38461538461539,85.50769230769231,86.63076923076923,87.75384615384615,88.87692307692308,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.4,76.19000000000001,76.98,77.77000000000001,78.56,79.35000000000001,80.14,80.93,81.72,82.51,83.3,84.09,84.88,{"y":85.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.4,75.52307692307693,75.64615384615385,75.76923076923077,75.8923076923077,76.01538461538462,76.13846153846154,76.26153846153846,76.38461538461539,76.50769230769231,76.63076923076923,76.75384615384615,76.87692307692308,{"y":77,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.55,"date":1522540800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1525132800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1533081600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1535760000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.55,"date":1538352000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.83,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.66,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.43,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >